These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38367265)

  • 1. Drug Repositioning for Ovarian Cancer Treatment: An Update.
    Cavalluzzi MM; Viale M; Rotondo NP; Ferraro V; Lentini G
    Anticancer Agents Med Chem; 2024; 24(8):637-647. PubMed ID: 38367265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.
    Kobayashi Y; Banno K; Kunitomi H; Tominaga E; Aoki D
    J Gynecol Oncol; 2019 Jan; 30(1):e10. PubMed ID: 30479094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.
    Nunes M; Henriques Abreu M; Bartosch C; Ricardo S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs Repurposing in High-Grade Serous Ovarian Cancer.
    Torralba M; Farra R; Maddaloni M; Grassi M; Dapas B; Grassi G
    Curr Med Chem; 2020; 27(42):7222-7233. PubMed ID: 32660396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in drug repositioning for the discovery of new anticancer drugs.
    Shim JS; Liu JO
    Int J Biol Sci; 2014; 10(7):654-63. PubMed ID: 25013375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational drug repositioning for cancer therapeutics.
    Jiao M; Liu G; Xue Y; Ding C
    Curr Top Med Chem; 2015; 15(8):767-75. PubMed ID: 25732789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs are not enough‑drug repositioning in oncology: An update.
    Armando RG; Mengual Gómez DL; Gomez DE
    Int J Oncol; 2020 Mar; 56(3):651-684. PubMed ID: 32124955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
    Nagaraj AB; Wang QQ; Joseph P; Zheng C; Chen Y; Kovalenko O; Singh S; Armstrong A; Resnick K; Zanotti K; Waggoner S; Xu R; DiFeo A
    Oncogene; 2018 Jan; 37(3):403-414. PubMed ID: 28967908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting Non-Cancer Drugs for Cancer Therapy.
    Yang EJ; Wu C; Liu Y; Lv J; Sup Shim J
    Curr Top Med Chem; 2016; 16(19):2144-55. PubMed ID: 26881712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer Drug Discovery By Structure-Based Repositioning Approach.
    Modh DH; Kulkarni VM
    Mini Rev Med Chem; 2024; 24(1):60-91. PubMed ID: 37165589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encapsulation of chloroquine and doxorubicin by MPEG-PLA to enhance anticancer effects by lysosomes inhibition in ovarian cancer.
    Shao M; Zhu W; Lv X; Yang Q; Liu X; Xie Y; Tang P; Sun L
    Int J Nanomedicine; 2018; 13():8231-8245. PubMed ID: 30584297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.
    Würth R; Thellung S; Bajetto A; Mazzanti M; Florio T; Barbieri F
    Drug Discov Today; 2016 Jan; 21(1):190-199. PubMed ID: 26456577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
    Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
    Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on human ovarian adenocarcinoma and lung carcinoma cells.
    Cavalluzzi MM; Viale M; Bruno C; Carocci A; Catalano A; Carrieri A; Franchini C; Lentini G
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4820-3. PubMed ID: 23886686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets.
    Mudduluru G; Walther W; Kobelt D; Dahlmann M; Treese C; Assaraf YG; Stein U
    Drug Resist Updat; 2016 May; 26():10-27. PubMed ID: 27180307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing Metformin for Cancer Treatment: A Great Challenge of a Promising Drug.
    Saengboonmee C; Sanlung T; Wongkham S
    Anticancer Res; 2021 Dec; 41(12):5913-5918. PubMed ID: 34848445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing old drugs to fight multidrug resistant cancers.
    Dinić J; Efferth T; García-Sosa AT; Grahovac J; Padrón JM; Pajeva I; Rizzolio F; Saponara S; Spengler G; Tsakovska I
    Drug Resist Updat; 2020 Sep; 52():100713. PubMed ID: 32615525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational agents for epithelial ovarian cancer.
    Muggia F; Kosloff R
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
    Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J
    Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double Repositioning: Veterinary Antiparasitic to Human Anticancer.
    Sultana T; Jan U; Lee JI
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.